NASDAQ:SRPTSarepta Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sarepta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $153.00 -4.16 (-2.65 %) (As of 05/29/2020 09:32 AM ET) Add Compare Share Today's Range$151.99Now: $153.00▼$156.8450-Day Range$99.98MA: $125.78▼$157.1652-Week Range$72.05Now: $153.00▼$158.80Volume1.37 million shsAverage Volume974,353 shsMarket Capitalization$11.93 billionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company's pipeline comprise SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA. It has collaboration agreements with Nationwide Children's Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; Galgt2, a gene therapy program for the treatment of DMD; and Neutrophin 3, a gene therapy program to treat Charcot-Marie-Tooth neuropathies. The company also has a license agreement with Lysogene to develop LYS-SAF302, a gene therapy for mucopolysaccharidosis IIIA; a license and option agreement with Lacerta to develop treatments for CNS-targeted and lysosomal storage diseases; and research collaboration and option agreement with Genethon to develop micro-dystrophin gene therapy products. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a collaboration agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline; a strategic collaboration with Paragon Bioservices; and a strategic collaboration with CENTOGENE for the identification of patients with DMD in the Middle East and North Africa region. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.96, and is based on 23 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $197.86, Sarepta Therapeutics has a potential upside of 29.3% from its current price of $153.00.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.1 Community Rank Outperform VotesSarepta Therapeutics has received 1,315 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSarepta Therapeutics has received 774 “underperform” votes. (Add your “underperform” vote.)Community SentimentSarepta Therapeutics has received 62.95% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sarepta Therapeutics and other stocks. Vote “Outperform” if you believe SRPT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SRPT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,575,450.00 in company stock.Percentage Held by InsidersOnly 6.60% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions93.08% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow in the coming year, from ($7.52) to ($4.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is -17.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 10.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone617-274-4000Debt Debt-to-Equity Ratio0.66 Current Ratio8.31 Quick Ratio7.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$380.83 million Price / Sales31.33 Cash FlowN/A Price / Cash FlowN/A Book Value$14.68 per share Price / Book10.42Profitability EPS (Most Recent Fiscal Year)($9.71) Net Income$-715,080,000.00 Net Margins-160.96% Return on Equity-64.67% Return on Assets-31.92%Miscellaneous Employees499 Outstanding Shares77,990,000Market Cap$11.93 billion Next Earnings Date8/5/2020 (Estimated) OptionableOptionable NASDAQ:SRPT Rates by TradingView Receive SRPT News and Ratings via Email Sign-up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Sarepta Therapeutics (NASDAQ:SRPT) Frequently Asked Questions How has Sarepta Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Sarepta Therapeutics' stock was trading at $102.8150 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SRPT shares have increased by 48.8% and is now trading at $153.00. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sarepta Therapeutics? 24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last year. There are currently 1 hold rating and 23 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sarepta Therapeutics. When is Sarepta Therapeutics' next earnings date? Sarepta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Sarepta Therapeutics. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics Inc (NASDAQ:SRPT) posted its quarterly earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.17) by $1.94. The biotechnology company earned $113.67 million during the quarter, compared to analyst estimates of $118.18 million. Sarepta Therapeutics had a negative return on equity of 64.67% and a negative net margin of 160.96%. The business's quarterly revenue was up 30.6% on a year-over-year basis. During the same period last year, the company earned ($1.07) earnings per share. View Sarepta Therapeutics' earnings history. What price target have analysts set for SRPT? 24 equities research analysts have issued 12-month target prices for Sarepta Therapeutics' stock. Their forecasts range from $160.00 to $260.00. On average, they expect Sarepta Therapeutics' stock price to reach $197.86 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View analysts' price targets for Sarepta Therapeutics. What are Wall Street analysts saying about Sarepta Therapeutics stock? Here are some recent quotes from research analysts about Sarepta Therapeutics stock: 1. According to Zacks Investment Research, "Sarepta's DMD drug, Exondys 51, posted impressive growth in 2019. Sarepta is focused on reimbursement programs for better accessibility of the drug. The company continues to make progress with its DMD pipeline. The approval to Vyondys 53 in December 2019 is likely to boost the company’s prospects as it will increase the eligible DMD patient population. However, dependence on a single product, Exondys 51, remains a concern. The company is yet to gain approval for Exondys 51 in the EU. The company has also faced other pipeline and regulatory setbacks. Moreover, the DMD market is getting competitive as several other companies are developing therapies. Estimates movement have been mixed ahead of Q1 earnings. The company has a mixed record of earnings surprises in the recent quarters." (5/2/2020) 2. Evercore ISI analysts commented, "We intend in connection with our next trial or set of trials associated with commercial material to address those issues and won’t move some of the restrictions that out of an overabundance or an abundance of caution exists within the protocol for what we call [indiscernible] (55:07) and now Study 102. So that our ultimate goal is to have the broadest possible coverage both of patients, age groups, geography but also genotype as well." (8/8/2019) Has Sarepta Therapeutics been receiving favorable news coverage? Media headlines about SRPT stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sarepta Therapeutics earned a news sentiment score of 0.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent news coverage is very unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSarepta Therapeutics. Who are some of Sarepta Therapeutics' key competitors? Some companies that are related to Sarepta Therapeutics include ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Genmab A/S (GMAB), BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), GALAPAGOS NV/S (GLPG), Beigene (BGNE) and Catalent (CTLT). View all competitors. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV). Who are Sarepta Therapeutics' key executives? Sarepta Therapeutics' management team includes the following people: Mr. Douglas S. Ingram, Pres, CEO & Director (Age 56)Mr. Sandesh Mahatme LL.M., Exec. VP, CFO & Chief Bus. Officer (Age 54)Mr. David Tyronne Howton Jr., Exec. VP, Gen. Counsel & Corp. Sec. (Age 47)Mr. Alexander Bo Cumbo, Exec. VP & Chief Commercial Officer (Age 48)Dr. Edward M. Kaye, Advisor (Age 70) What is Sarepta Therapeutics' stock symbol? Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT." Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sands Capital Management LLC (5.65%), Capital Research Global Investors (4.97%), Janus Henderson Group PLC (4.52%), Waddell & Reed Financial Inc. (1.45%), Wellington Management Group LLP (1.21%) and Orbimed Advisors LLC (1.16%). Company insiders that own Sarepta Therapeutics stock include Alexander Cumbo, David T Howton, Douglas S Ingram, Hans Lennart Rudolf Wigzell, M Kathleen Behrens, Michael W Bonney, Richard Barry and Sandesh Mahatme. View institutional ownership trends for Sarepta Therapeutics. Which institutional investors are selling Sarepta Therapeutics stock? SRPT stock was sold by a variety of institutional investors in the last quarter, including Alyeska Investment Group L.P., Sands Capital Management LLC, Deutsche Bank AG, Fred Alger Management LLC, Cormorant Asset Management LP, First Trust Advisors LP, California Public Employees Retirement System, and Tekla Capital Management LLC. Company insiders that have sold Sarepta Therapeutics company stock in the last year include Alexander Cumbo, David T Howton, Hans Lennart Rudolf Wigzell, Richard Barry, and Sandesh Mahatme. View insider buying and selling activity for Sarepta Therapeutics. Which institutional investors are buying Sarepta Therapeutics stock? SRPT stock was bought by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Janus Henderson Group PLC, Capital International Investors, Orbimed Advisors LLC, Camber Capital Management LP, Sphera Funds Management LTD., Federated Hermes Inc., and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Sarepta Therapeutics stock in the last two years include Douglas S Ingram, M Kathleen Behrens, Michael W Bonney, and Richard Barry. View insider buying and selling activity for Sarepta Therapeutics. How do I buy shares of Sarepta Therapeutics? Shares of SRPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sarepta Therapeutics' stock price today? One share of SRPT stock can currently be purchased for approximately $153.00. How big of a company is Sarepta Therapeutics? Sarepta Therapeutics has a market capitalization of $11.93 billion and generates $380.83 million in revenue each year. The biotechnology company earns $-715,080,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Sarepta Therapeutics employs 499 workers across the globe. What is Sarepta Therapeutics' official website? The official website for Sarepta Therapeutics is www.sareptatherapeutics.com. How can I contact Sarepta Therapeutics? Sarepta Therapeutics' mailing address is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-274-4000 or via email at [email protected] This page was last updated on 5/29/2020 by MarketBeat.com Staff
